Arch Re to Acquire Global Credit & Surety Renewal Rights From Aspen Re
Arch Reinsurance (Arch Re), a wholly owned subsidiary of Arch Capital Group Ltd. (ACGL), and Aspen Reinsurance (Aspen Re), the reinsurance business segment of Aspen Insurance Holdings Limited (Aspen), jointly announced that Arch Re has entered into a renewal rights agreement with Aspen Re on its global credit and surety reinsurance business after Aspen Re’s decision to exit the line. In addition to the renewal rights on the portfolio, the parties have agreed to initiate additional discussions about the potential novation of the existing book in the coming months.
Arch has extended employment offers to all of Aspen Re’s Zurich-based credit and surety employees to join Arch Re’s existing credit and surety team based in Zurich.
“This is a unique opportunity for us to not only augment and diversify our credit and surety portfolio through the acquisition of Aspen Re’s renewal rights, but to also add talented employees to our team,” said Michael Hammer, President and CEO of Arch Re Europe. “We appreciate working with Aspen to bring the two teams together and look forward to enhancing our overall service offering to our clients.”
Christian Dunleavy, Chief Underwriting Officer of Aspen Re said, “We are very pleased to have reached agreement with Arch Re for the renewal of our reinsurance credit and surety business as we seek to create a more simple and focused reinsurance business at Aspen Re. This agreement with Arch Re facilitates continuity for both our staff and cedents with a strong counterparty, which was a critical consideration. We would like to wish our cedents and the credit and surety team well for their future with Arch Re.”
Richard Lange, Head of Credit and Surety at Arch Re Europe, said, “We welcome the opportunity to add to the Arch team and provide top level service along with a large balance sheet to Aspen Re’s existing clients and brokers. We hope to earn these clients’ trust and to begin and sustain a long term relationship with them.”
About Arch Worldwide Reinsurance Group
Arch Worldwide Reinsurance Group, a part of Arch Capital Group Ltd., provides reinsurance to its clients around the globe. With offices in North America, Bermuda, Europe and Australia, Arch Worldwide Reinsurance offers specialty risk solutions through treaty and facultative property and casualty reinsurance with a disciplined underwriting approach.
About Arch Capital Group Ltd.
Arch Capital Group Ltd., a Bermuda-based company with approximately $12.89 billion in capital at Sept. 30, 2019, provides insurance, reinsurance and mortgage insurance on a worldwide basis through its wholly owned subsidiaries.
Cautionary Note Regarding Forward-looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. This release or any other written or oral statements made by or on behalf of Arch Capital Group Ltd. and its subsidiaries may include forward-looking statements, which reflect our current views with respect to future events and financial performance. All statements other than statements of historical fact included in or incorporated by reference in this release are forward-looking statements.
Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or their negative or variations or similar terminology. Forward-looking statements involve our current assessment of risks and uncertainties. Actual events and results may differ materially from those expressed or implied in these statements. A non-exclusive list of the important factors that could cause actual results to differ materially from those in such forward-looking statements includes the following: adverse general economic and market conditions; increased competition; pricing and policy term trends; fluctuations in the actions of rating agencies and our ability to maintain and improve our ratings; investment performance; the loss of key personnel; the adequacy of our loss reserves, severity and/or frequency of losses, greater than expected loss ratios and adverse development on claim and/or claim expense liabilities; greater frequency or severity of unpredictable natural and man-made catastrophic events; the impact of acts of terrorism and acts of war; changes in regulations and/or tax laws in the United States or elsewhere; our ability to successfully integrate, establish and maintain operating procedures as well as integrate the businesses we have acquired or may acquire into the existing operations; changes in accounting principles or policies; material differences between actual and expected assessments for guaranty funds and mandatory pooling arrangements; availability and cost to us of reinsurance to manage our gross and net exposures; the failure of others to meet their obligations to us; and other factors identified in our filings with the U.S. Securities and Exchange Commission.
The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with other cautionary statements that are included herein or elsewhere. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005692/en/
Contact information
Arch Capital Services
Greg Hare
336 333 0416
ghare@archcapservices.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline4.9.2025 08:00:00 EEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB. Validation of Leadership Position in Microbiome-Based Therapeutics Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical da
Abbove Unveils “Mia”: Opening a New Chapter in Digital Wealth Planning in Europe4.9.2025 07:00:00 EEST | Press release
Abbove, the European platform for collaborative and family-centered wealth planning, announces today the launch of Mia, its new artificial intelligence agent. Used by more than 1,100 advisors and deployed to over 37,000 families across Europe, Abbove takes a major step forward in its mission to reimagine the wealth advisory experience in the digital age. Designed to enhance the capabilities of wealth advisors, family officers, and financial experts, Mia acts as an intelligent co-pilot. It simplifies the reading and analysis of complex estate documents, automatically extracts key information, and assists users in the understanding, enrichment, and structuring of wealth data. “The launch of Mia opens an entirely new functional AI vertical on our platform, unlocking near-infinite possibilities for future development. It’s a key milestone that brings us closer to our ambition of becoming the leading pan-European wealth planning platform.” — Guillaume Desclée, Founder & CEO of Abbove Native
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions4.9.2025 03:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/ Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and su
OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 20:23:00 EEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 19:19:00 EEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom